Under the settlement, Abbott will divest the rights and assets for its line of point-of-care blood gas testing systems to Siemens Aktiengelsellschaft and sell its point-of-care cardiac marker testing systems to Quidel Corporation. Abbott will also hand over two Ottawa, Canada-based facilities to Siemens and one San Diego-based facility to Quidel.
Abbott completed its acquisition of Alere in October. The FTC ruled the acquisition would likely hinder competition for these two types of medical devices in a September complaint.
More articles on supply chain:
Prime Healthcare taps HealthTrust for GPO services
Acorda Therapeutics halts Parkinson’s drug trials after 5 patient deaths
Cardinal Health to sell Chinese distribution business to Shanghai Pharma
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.